z-logo
open-access-imgOpen Access
Recent Advances in Potential Clinical Application of Ghrelin in Obesity
Author(s) -
Christine Delporte
Publication year - 2012
Publication title -
journal of obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 53
eISSN - 2090-0716
pISSN - 2090-0708
DOI - 10.1155/2012/535624
Subject(s) - ghrelin , growth hormone secretagogue receptor , appetite , endocrinology , medicine , gastric emptying , receptor , hormone , stomach
Ghrelin is the natural ligand of the growth hormone secretagogue receptor (GHS-R1a). Ghrelin is a 28 amino acid peptide possessing a unique acylation on the serine in position 3 catalyzed by ghrelin O-acyltransferase (GOAT). Ghrelin stimulates growth hormone secretion, but also appetite, food intake, weight gain, and gastric emptying. Ghrelin is involved in weight regulation, obesity, type 2 diabetes, and metabolic syndrome. Furthermore, a better understanding of ghrelin biology led to the identification of molecular targets modulating ghrelin levels and/or its biological effects: GOAT, ghrelin, and GHS-R1a. Furthermore, a recent discovery, showing the involvement of bitter taste receptor T2R in ghrelin secretion and/or synthesis and food intake, suggested that T2R could represent an additional interesting molecular target. Several classes of ghrelin-related pharmacological tools for the treatment of obesity have been or could be developed to modulate the identified molecular targets.Journal ArticleSCOPUS: re.jinfo:eu-repo/semantics/publishe

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom